Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

Brain

Volumn 138, Issue 11, 2015, Pages 3275-3286

  Iaffaldano, Pietro ^a   Lucisano, Giuseppe ^a,b   Pozzilli, Carlo ^c   Brescia Morra, Vincenzo ^d   Ghezzi, Angelo ^e   Millefiorini, Enrico ^f   Patti, Francesco ^g   Lugaresi, Alessandra ^h   Zimatore, Giovanni Bosco ⁱ   Marrosu, Maria Giovanna ^j   Amato, Maria Pia ^k   Bertolotto, Antonio ^l   Bergamaschi, Roberto ^m   Granella, Franco ⁿ   Coniglio, Gabriella ^o   Tedeschi, Gioacchino ^p   Sola, Patrizia ^q   Lus, Giacomo ^d   Ferrò, Maria Teresa ^r   Iuliano, Gerardo ^s   Corea, Francesco ^t   Protti, Alessandra ^u   Cavalla, Paola ^v   Guareschi, Angelica ^w   Rodegher, Mariaemma ^x   Paolicelli, Damiano ^a   Tortorella, Carla ^a   Lepore, Vito ^b   Prosperini, Luca ^c   Saccà, Francesco ^d   Baroncini, Damiano ^e   Comi, Giancarlo ^x   Trojano, Maria ^a   more..

^a UNIVERSITY OF BARI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ R Dimiccoli Hospital Department of Gaastroenterology   (Italy)

^j UNIVERSITY OF CAGLIARI   (Italy)

^k UNIVERSITY OF FLORENCE   (Italy)

^l SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^m C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

ⁿ UNIVERSITY OF PARMA   (Italy)

^o MADONNA DELLE GRAZIE HOSPITAL   (Italy)

^p SECOND UNIVERSITY OF NAPLES   (Italy)

^q UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^r MAGGIORE HOSPITAL   (Italy)

^s University Hospital San Giovanni di Dio   (Italy)

^t SGiovanni Battista Hospital   (Italy)

^u OSPEDALE NIGUARDA CA GRANDA   (Italy)

^v CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^w Fidenza Hospital   (Italy)

^x SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

fingolimod; glatiramer acetate; interferon beta; multiple sclerosis; natalizumab discontinuation

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INCIDENCE; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPENSITY SCORE; PROSPECTIVE STUDY; RELAPSE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG SUBSTITUTION; ITALY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POISSON DISTRIBUTION; REGISTER; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FINGOLIMOD HYDROCHLORIDE; GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REGISTRIES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84947790954     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv260     Document Type: Article

References (28)

1. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-53.
2. Borriello G, Prosperini L, Marinelli F, Fubelli F,Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011; 17: 372-5.
3. Borriello G, Prosperini L, Mancinelli C, Gianni C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012; 19: 783-7.
4. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79: 2004-5.
5. Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 2014; 71: 954-60. doi: 10. 1001/jamaneurol. 2014. 1200.
6. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
7. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013; 260: 2023-32.
8. Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, et al. Switching from Natalizumab to Fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014; 71: 436-41.
9. doi: 10. 1001/jamaneurol. 2013. 6240.
10. Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P, Tomic D, et al. Relapses in patients treated with fingolimod after previous exposure to natalizumab. Mult Scler 2014; 21: 786-90. pii: 1352458514549404.
11. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491-8.
12. Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011; 258: 1665-9.
13. Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2013; 260: 1382-7. doi: 10. 1007/s00415-012-6808-8.
14. Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014; 82: 1204-11.
15. Kaufman MD, Lee R, Norton HJ. Course of relapsing remitting multiple sclerosis before, during and after natalizumab. Mult Scler 2011; 17: 490-4.
16. Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98-102.
17. Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68: 392-5.
18. Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Mult Scler 2013; 19: 1236-7. doi: 10. 1177/1352458512468498.
19. Magraner MJ, Coret F, Navarre A, Boscá I, Simó M, Escutia M, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011; 258: 1805-11.
20. O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-65.
21. Parsons LS. Reducing bias in a propensity score matched pair sample using greedy matching techniques. In: Proceedings of the twentysixth annual SAS Users Group International Conference. Cary, NC: SAS Institute; 2004.
22. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
23. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640-3. doi: 10. 1177/1352458512464282.
24. Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2013; 20: 87-94.
25. Sempere AP, Martn-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013; 128: e6-10. doi: 10. 1111/ane. 12082.
26. Stuve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72: 396-401.
27. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-9.
28. Yanovitzky I, Zanutto E, Hornik R. Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 2005; 28: 209-20.